Table 1 Patient characteristics.
Baseline characteristics. | All patients (n = 34) | No active cGvHD (n = 24) | Active cGvHD (n = 10) |
|---|---|---|---|
Diagnosis | |||
Acute myeloid leukemia (AML) | 14 (41%) | 11 (46%) | 3 (30%) |
Acute lymphoblastic leukemia (ALL) | 5 (15%) | 3 (13%) | 2 (20%) |
Chronic myeloid leukemia (CML) | 6 (18%) | 3 (13%) | 3 (30%) |
Lymphoma | 3 (9%) | 1 (4%) | 2 (20%) |
Myelofibrosis | 2 (6%) | 2 (8%) | 0 |
Other2 | 4 (12%) | 4 (17%) | 0 |
Sex | |||
Male | 16 (47%) | 11 (46%) | 5 (50%) |
Female | 18 (53%) | 13 (54%) | 5 (50%) |
Reduced intensity (RIC) or Myeloablative conditioning (MAC) | |||
RIC | 15 (44%) | 11 (46%) | 4 (40%) |
MAC | 19 (56%) | 13 (54%) | 6 (60%) |
cGvHD-severity | |||
Mild | 4 (12%) | 4 (40%) | |
Moderate | 3 (9%) | 3 (30%) | |
Severe | 3 (9%) | 3 (30%) | |
Ongoing GvHD-therapy at vaccination | |||
Systemic IST3 | 6 (18%) | 6 (60%) | |
Topical | 3 (9%) | 3 (30%) | |
No ongoing GvHD-therapy | 25 (71%) | 24 (100%) | 1 (10%) |
Previous COVID-19 infection | |||
Confirmed by PCR | 7 (21%) | 5 (21%) | 2 (20%) |
Symptoms + positive antigen test | 8 (24%) | 4 (17%) | 4 (40%) |
Positive nIgG only | 6 (18%) | 3 (13%) | 3 (30%) |
A combination of above | 6 (18%) | 3 (13%) | 3 (30%) |
Vaccination details | |||
Age at vaccination in years (median, min-max) | 56 (30–81) | 62 (30–81) | 44 (32–79) |
Time since last vaccine dose (months: median, min-max) | 13 (2–30) | 12 (2–23) | 13 (3–30) |
Number of previous vaccine doses (median, min-max) | 4 (21-6) | 4 (2–5) | 4 (21-6) |
Previous COVID-19 mRNA vaccine (BNT162b2 (Pfizer-BioBTech Comirnaty)/ mRNA-1273 (Moderna Spikevax)/mix of both vaccines/not sure | 18/3/5/8 | 10/2/5/7 | 8/1/0/1 |
Time from transplant at booster (months: median, min-max) | 101 (11–277) | 101 (11–277) | 101 (34–249) |
